Asthma

Findings from a post hoc analysis of the phase 3 DIRECTION study highlight tezepelumab’s consistent benefit on asthma exacerbations across trigger categories.

At ATS 2025, these data highlight a potential connection between asthma development and prenatal exposure to microplastics and other forms of pollution.

The approval adds to Ritestar’s currently approved albuterol sulfate 2.5 mg/3 mL (0.083%), 1.25 mg/3 mL, and 0.63 mg/3 mL strength products.

Results highlight dupilumab’s real-world benefit for asthma control in patients with and without coexisting chronic rhinosinusitis and/or nasal polyposis.

This analysis highlights rademikibart’s effect on blood eosinophil counts in those with asthma, exploring whether there was an IL-4Rα class effect.

The ProVENT data highlight dupilumab’s efficacy in treating severe asthma, with improvements in control, quality of life, and exacerbations being observed.

Phase 3 BATURA data reveal a 47% reduction in the risk of severe exacerbations in mild asthma with albuterol/budesonide (Airsupra) versus albuterol alone.

In this analysis, investigators found consistent benefits over placebo among children with type 2 asthma treated with dupilumab, regardless of condition length.

Long-term studies reveal that benralizumab achieves sustained remission in severe eosinophilic asthma, significantly reducing exacerbations in older adults.

This month’s Lungcast features a discussion on the ALA’s State of the Air report and how worsening air conditions affect people across the nation.

Explore innovative strategies for asthma management that prioritize shared decision-making and address environmental, social, and behavioral factors.

A recent study reveals that asthma-COPD overlap does not significantly worsen outcomes in well-managed severe asthma patients.

The asthma-related emergency department visits highlighted here, following the Canadian wildfires near Ontario, were attributed to smoke inhalation.

New findings reveal that higher HbA1c levels worsen asthma control in children, linking metabolic dysfunction to increased asthma morbidity.

Digital inhalers enhance asthma control and reduce severe exacerbations, offering promising benefits with minimal harm for patients struggling with adherence.

AI enhances prediction, diagnosis, and treatment of allergic diseases including asthma, atopic dermatitis, and food allergies, offering personalized, efficient care.

New triple therapy BGF shows significant and clinically meaningful lung function improvement in patients with uncontrolled asthma, with full data readouts coming soon.

The month in review spotlights new data for COPD and bronchiectasis, as well as new research and conversations around smoking.

Overall, Asthma Control Test (ACT) measures improved by 37%.

Acute respiratory infection caused by RSV results in a nearly 3-fold increase in mortality, particularly in those with underlying respiratory conditions.

Our Q1 2025 recap for pulmonology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in pulmonology care. Read now:

Participants with higher baseline eosinophil levels had the greatest responses and no participants experienced peaks of over 3000 eosinophils/µL.

This March 2025 month in review covers key pulmonology updates, including new findings on pulmonary function tests and expert insights from the AAAAI/WAO Joint Congress.

A new cross-sectional study found that the odds of having bronchodilator responsiveness declined by 8% per hour during the working day.

Our top 5 headlines featured an oral drug delivering 16% weight loss, notable blood pressure reductions from a hypertension treatment, and 3 key FDA decisions.